Composition

Abstract

To provide a composition having excellent anti-aging properties. [Solution] (A) Nicotinamide mononucleotide and / or pyrroloquinoline quinone, (B) At least one specific other material selected from the group consisting of (a) to (d) below, An oral or topical composition characterized by containing [a certain substance]. (a) At least one functional material selected from the group consisting of genistein, isoquercitrin, ginsenoside, papain, glutathione, and lactic acid bacteria. (b) At least one plant material selected from the group consisting of grapes, maca, pine bark, kudzu flowers, Terminalia bellirica, Indian mangosteen, black ginger, and willowherb. (c) At least one vitamin selected from the group consisting of vitamins B and D (d) Leucine

Description

[[Technical Field]]

[0001] The present invention relates to a composition containing nicotinamide mononucleotide and / or pyrroloquinoline quinone and specific other raw materials. [[Background Art]]

[0002] In Japan, the lifespan of people itself has been extended due to the development of medical technology. On the other hand, people face problems such as impaired daily life and susceptibility to various diseases caused by the decline in physical and mental functions accompanying aging. Functional decline that occurs with aging is generally called aging, and examples thereof include declines in vision, hearing, memory, motor ability, immune function, organ function and the like. Therefore, suppressing aging is desired from the viewpoint of improving the quality of life, and prevention using foods and cosmetics that can be used safely over a long period of time is important. Accordingly, the development of foods and cosmetics that exert such effects is expected.

[0003] As foods and cosmetics for suppressing aging, for example, resveratrol (Non-Patent Document 1) is known. However, many conventional anti-aging compositions do not necessarily have sufficiently high effects. [[Prior Art Documents]] [[Non-Patent Documents]]

[0004] [[Non-Patent Document 1]] Small molecule activators of sirtuins extend Saccharomyces cerevisiae lifespan.Nature,425:191-196,2003. [[Summary of the Invention]] [[Problem to be Solved by the Invention]]

[0005] An object of the present invention is to provide a composition that can be used safely over a long period of time and exhibits an excellent anti-aging effect. [Means for solving the problem]

[0006] The inventors of this invention, after diligently conducting research to solve the above problems, have surprisingly discovered that combining nicotinamide mononucleotide and / or pyrroloquinoline quinone with at least one of specific other materials exhibits excellent anti-aging effects. This invention is a completed invention based on this finding.

[0007] In other words, the present invention is as follows: [1](A) Nicotinamide mononucleotide and / or pyrroloquinoline quinone, (B) At least one specific other material selected from the group consisting of (a) to (d) below, A composition characterized by containing the following: (a) At least one functional material selected from the group consisting of genistein, isoquercitrin, ginsenoside, papain, glutathione, and lactic acid bacteria. (b) At least one plant material selected from the group consisting of grapes, maca, pine bark, kudzu flowers, Terminalia bellirica, Indian mangosteen, black ginger, and willowherb. (c) At least one vitamin selected from the group consisting of vitamins B and D (d) Leucine [2](A) Nicotinamide mononucleotide and / or pyrroloquinoline quinone, (B) At least one specific other material selected from the group consisting of (a) to (d) below, An oral composition characterized by containing [a certain substance]. (a) At least one functional material selected from the group consisting of genistein, isoquercitrin, ginsenoside, papain, glutathione, and lactic acid bacteria. (b) At least one plant material selected from the group consisting of grapes, maca, pine bark, kudzu flowers, Terminalia bellirica, Indian mangosteen, black ginger, and willowherb. (c) At least one vitamin selected from the group consisting of vitamins B and D (d) Leucine [3](A) Nicotinamide mononucleotide and / or pyrroloquinoline quinone, (B) At least one specific other material selected from the group consisting of (a) to (d) below, An external composition characterized by containing [a certain substance]. (a) At least one functional material selected from the group consisting of genistein, isoquercitrin, ginsenoside, papain, glutathione, and lactic acid bacteria. (b) At least one plant material selected from the group consisting of grapes, maca, pine bark, kudzu flowers, Terminalia bellirica, Indian mangosteen, black ginger, and willowherb. (c) At least one vitamin selected from the group consisting of vitamins B and D (d) Leucine [4] (A) Nicotinamide mononucleotide and / or pyrroloquinoline quinone, (B) At least three specific other materials selected from the group consisting of (a) to (d) below, An oral or topical composition characterized by containing [a certain substance]. (a) At least one functional material selected from the group consisting of genistein, isoquercitrin, ginsenoside, papain, glutathione, and lactic acid bacteria. (b) At least one plant material selected from the group consisting of grapes, maca, pine bark, kudzu flowers, Terminalia bellirica, Indian mangosteen, black ginger, and willowherb. (c) At least one vitamin selected from the group consisting of vitamins B and D (d) Leucine [5] The composition according to any one of [1] to [5] above, wherein the mass ratio of component (A) to component (B) is (A):(B) = 1:0.0001 to 1. [6] An oral composition according to any one of the above [1] to [5], characterized in that it is a food product. [7] An oral composition according to any one of the above [1] to [6], characterized in that it is a nutritional functional food. [8] A composition according to any of [1] to [7] above, which is for anti-aging purposes. [9] A composition according to any of [1] to [8] above, for promoting mitochondrial activity.

[10] A composition according to any of [1] to [9] above, for nutritional supplementation.

[11] A beauty composition according to any of the above [1] to [9].

[12] An oral composition according to any of [1] to

[11] above, designed so that the daily intake of component (A) for adults is 0.01 mg to 1000 mg.

[13] An oral composition according to any of [1] to

[12] above, designed so that the daily intake of component (B) for adults is 0.01 mg to 50 mg.

[14] A composition according to any of [1] to

[13] above, for the purpose of maintaining or improving vitality.

[15] A composition according to any one of [1] to

[15] above, for the purpose of maintaining the health of the skin or mucous membranes.

[16] A composition according to any one of [1] to

[16] above, for promoting protein metabolism.

[17] A composition according to any of the above [1] to

[13] that displays the following: firm days, vibrant days, desire to stay youthful, defy age, desire to continue to shine beautifully, anti-aging care.

[18] (A) Nicotinamide mononucleotide and / or pyrroloquinoline quinone, At least one specific other material selected from the group consisting of (a) below, At least one specific other material selected from the group consisting of (b) to (d) below, A composition characterized by containing the following. (a) At least one functional material selected from the group consisting of genistein, isoquercitrin, ginsenoside, papain, glutathione, and lactic acid bacteria. (b) At least one plant material selected from the group consisting of grapes, maca, pine bark, kudzu flowers, Terminalia bellirica, Indian mangosteen, black ginger, and willowherb. (c) at least one vitamin selected from the group consisting of vitamin B and vitamin D (d) leucine

[19] (A) nicotinamide mononucleotide and / or pyrroloquinoline quinone, and at least one specific other material selected from the group consisting of the following (b), and at least one specific other material selected from the group consisting of the following (a), (c) and (d), A composition characterized by comprising: (a) at least one functional material selected from the group consisting of genistein, isoquercitrin, ginsenoside, papain, glutathione and lactic acid bacteria (b) at least one plant material selected from the group consisting of grape, maca, pine bark, kudzu flower, Terminalia bellirica, Garcinia mangostana, black ginger and Epilobium parviflorum (c) at least one vitamin selected from the group consisting of vitamin B and vitamin D (d) leucine

[20] (A) nicotinamide mononucleotide and / or pyrroloquinoline quinone, and at least one specific other material selected from the group consisting of the following (c), and at least one specific other material selected from the group consisting of the following (a), (b) and (d), A composition characterized by comprising: (a) at least one functional material selected from the group consisting of genistein, isoquercitrin, ginsenoside, papain, glutathione and lactic acid bacteria (b) at least one plant material selected from the group consisting of grape, maca, pine bark, kudzu flower, Terminalia bellirica, Garcinia mangostana, black ginger and Epilobium parviflorum (c) at least one vitamin selected from the group consisting of vitamin B and vitamin D (d) leucine

[21] (A) nicotinamide mononucleotide and / or pyrroloquinoline quinone, and At least one specific other material selected from the group consisting of (d) below, At least one specific other material selected from the group consisting of (a) to (c) below, A composition characterized by containing the following. (a) At least one functional material selected from the group consisting of genistein, isoquercitrin, ginsenoside, papain, glutathione, and lactic acid bacteria. (b) At least one plant material selected from the group consisting of grapes, maca, pine bark, kudzu flowers, Terminalia bellirica, Indian mangosteen, black ginger, and willowherb. (c) At least one vitamin selected from the group consisting of vitamins B and D (d) Leucine

[22] (A) Nicotinamide mononucleotide and / or pyrroloquinoline quinone, At least one specific other material selected from the group consisting of (a) below, At least one specific other material selected from the group consisting of (b) below, and At least one specific other material selected from the group consisting of (c) below, A composition characterized by containing the following. (a) At least one functional material selected from the group consisting of genistein, isoquercitrin, ginsenoside, papain, glutathione, and lactic acid bacteria. (b) At least one plant material selected from the group consisting of grapes, maca, pine bark, kudzu flowers, Terminalia bellirica, Indian mangosteen, black ginger, and willowherb. (c) At least one vitamin selected from the group consisting of vitamins B and D

[23] (A) Nicotinamide mononucleotide and / or pyrroloquinoline quinone, At least one specific other material selected from the group consisting of (a) below, At least one specific other material selected from the group consisting of (b) below, and At least one specific other material selected from the group consisting of (d) below, A composition characterized by containing the following. (a) At least one functional material selected from the group consisting of genistein, isoquercitrin, ginsenoside, papain, glutathione, and lactic acid bacteria. (b) At least one plant material selected from the group consisting of grapes, maca, pine bark, kudzu flowers, Terminalia bellirica, Indian mangosteen, black ginger, and willowherb. (d) Leucine

[24] (A) Nicotinamide mononucleotide and / or pyrroloquinoline quinone, At least one specific other material selected from the group consisting of (a) below, At least one specific other material selected from the group consisting of (c) below, and At least one specific other material selected from the group consisting of (d) below, A composition characterized by containing the following. (a) At least one functional material selected from the group consisting of genistein, isoquercitrin, ginsenoside, papain, glutathione, and lactic acid bacteria. (c) At least one vitamin selected from the group consisting of vitamins B and D (d) Leucine

[25] (A) Nicotinamide mononucleotide and / or pyrroloquinoline quinone, At least one specific other material selected from the group consisting of (b) below, At least one specific other material selected from the group consisting of (c) below, and At least one specific other material selected from the group consisting of (d) below, A composition characterized by containing the following. (b) At least one plant material selected from the group consisting of grapes, maca, pine bark, kudzu flowers, Terminalia bellirica, Indian mangosteen, black ginger, and willowherb. (c) At least one vitamin selected from the group consisting of vitamins B and D (d) Leucine

[26] (A) Nicotinamide mononucleotide and / or pyrroloquinoline quinone, At least one specific other material selected from the group consisting of (a) below, At least one specific other material selected from the group consisting of (b) below, At least one specific other material selected from the group consisting of (c) below, and At least one specific other material selected from the group consisting of (d) below, A composition characterized by containing the following. (a) At least one functional material selected from the group consisting of genistein, isoquercitrin, ginsenoside, papain, glutathione, and lactic acid bacteria. (b) At least one plant material selected from the group consisting of grapes, maca, pine bark, kudzu flowers, Terminalia bellirica, Indian mangosteen, black ginger, and willowherb. (c) At least one vitamin selected from the group consisting of vitamins B and D (d) Leucine [Effects of the Invention]

[0008] According to the present invention, by including nicotinamide mononucleotide and / or pyrroloquinoline quinone and certain other materials, a composition with excellent anti-aging properties can be provided. [Modes for carrying out the invention]

[0009] The following describes preferred embodiments of the present invention. However, the present invention is not limited to the embodiments shown below, and can be modified, added, altered, or deleted to the extent that a person skilled in the art can conceive of it. Any embodiment that achieves the effects and benefits of the present invention is included within the scope of the present invention.

[0010] The composition of the present invention is characterized by containing nicotinamide mononucleotide and / or pyrroloquinoline quinone and certain other materials. The certain other materials used with nicotinamide mononucleotide and / or pyrroloquinoline quinone may be used alone or in combination of two or more, but from the viewpoint of anti-aging effect, it is more preferable to use two or more in combination.

[0011] 1. Components constituting the present invention

[0012] The following describes each component included in the composition of the present invention.

[0013] The present invention contains (A) nicotinamide mononucleotide and / or pyrroloquinoline quinone (hereinafter sometimes referred to as component (A)).

[0014] The following details component (A).

[0015] (A-1) Nicotinamide mononucleotide Nicotinamide mononucleotide (chemical formula: C11H15N2O8P) is a nucleotide derived from ribose and nicotinamide, and is known as an intermediate metabolite involved in the biosynthesis of NAD+ (nicotinamide adenine dinucleotide). In the present invention, nicotinamide mononucleotide (hereinafter sometimes referred to as NMN) can be produced by fermentation using yeast or chemically synthesized, and is not particularly limited, but from the viewpoint of particularly demonstrating the effects of the present invention, it is preferable to use nicotinamide mononucleotide produced by fermentation using yeast.

[0016] In the present invention, the type of optical isomer of NMN is not limited; for example, α-isomers and β-isomers can be used. However, from the viewpoint of anti-aging effects, it is preferable to use the β-isomer (β-nicotinamide mononucleotide).

[0017] (A-2) Pyrroloquinoline quinone Pyrroloquinoline quinone (chemical formula: C14H6N2O8) is a quinone compound known as the third coenzyme after flavin and nicotinamide. In this invention, pyrroloquinoline quinone (hereinafter sometimes referred to as PQQ) may be the oxidized form represented by the following formula (1) (oxidized PQQ) or the reduced form represented by the following formula (2) (reduced PQQ).

[0018] [ka]

[0019] [ka]

[0020] Furthermore, the pyrroloquinoline quinone in the present invention may be in the form of a free form or a salt. Examples of pyrroloquinoline quinone salts include alkali metal salts, alkaline earth metal salts, and ammonium salts. The pyrroloquinoline quinone contained in the oral composition of the present invention can be extracted and purified from plants or fermented foods, or chemically synthesized, and commercially available products may also be used. Pyrroloquinoline quinone is found, for example, in plants such as parsley and bell peppers, and in fermented foods such as natto, tofu, and miso. Alternatively, plants or fermented foods containing pyrroloquinoline quinone may be used as is after being powdered or granulated. The extraction conditions are the same as those for glucosinolates described above. The amount of pyrroloquinoline quinone can be measured using high-performance liquid chromatography (HPLC).

[0021] The present invention contains (B) at least one specific other material selected from the group consisting of (a) to (d) below (hereinafter sometimes referred to as (B) component). (a) At least one functional material selected from the group consisting of genistein, isoquercitrin, ginsenoside, papain, glutathione, and lactic acid bacteria. (b) At least one plant material selected from the group consisting of grapes, maca, pine bark, kudzu flowers, Terminalia bellirica, Indian mangosteen, black ginger, and willowherb. (c) At least one vitamin selected from the group consisting of vitamins B and D (d) Leucine

[0022] The composition of the present invention may contain at least one specific other material selected from the group consisting of (a) to (d) above as component (B), but from the viewpoint of more significantly exhibiting the effects of the present invention, it is more preferable to contain components from two or more groups from the group consisting of (a) to (d), particularly preferable to contain components from three or more groups, and most preferable to contain components from four or more groups.

[0023] The following details component (B).

[0024] The composition of the present invention may contain, as component (B), at least one functional material selected from the group consisting of genistein, isoquercitrin, ginsenoside, papain, glutathione, and lactic acid bacteria.

[0025] (B-a1) Genistein Genistein (chemical formula: C15H10O5) is a type of isoflavone found in soybeans, along with daidzein and glycitein. It has a chemical structure similar to female hormones and is known to have weak hormonal effects. There are no particular restrictions on the origin or manufacturing method of the genistein used in this invention; for example, extracts from various plants containing genistein, or partially purified products thereof, may be used as appropriate, or commercially available products may be used.

[0026] (B-a2) Isoquercitrin Isoquercitrin (chemical formula: C21H20O12) is a flavonol glycoside in which glucose is β-bonded to the 3rd position of quercetin, a polyphenol component abundant in vegetables and fruits, and is known to have strong antioxidant activity. The isoquercitrin used in this invention is not particularly limited as long as it is commonly used in the food and beverage field. For example, extracts derived from various plants that are rich in isoquercitrin, or partially purified products thereof, may be used, or commercially available products may be used.

[0027] (B-a3) Ginsenoside Ginsenosides are a type of steroid saponin found in plants of the genus Panax in the family Araliaceae, derived from roots, stems, leaves, bark, seeds, etc. There are various types of ginsenosides, such as Rb1, Rb2, Rc, Rd, Re, and Rg1, and the type and content of ginsenosides present vary depending on the plant species, cultivation conditions, processing conditions, extraction method, and part of the plant. The type of ginsenoside used in this invention is not particularly limited and can be used in suitable combinations, but ginsenoside Rg1 is particularly preferred because it more effectively exhibits the effects of this invention.

[0028] (B-a4) Papain Papain is known to be obtained, for example, from immature papaya fruit and / or juice or processed products thereof. Papaya is a fruit native to tropical America and is not particularly limited to plants of the genus Carica, for example, Carica papaya. In the oral composition of this embodiment, papain may be in solid form, or it may be in liquid, paste, gel, jelly, cream, emulsion, spray, mousse, lotion, or other fluid form. Examples of solid forms include powder, granules, and granules. As for the protease such as papain, it is preferable to use one with a proteolytic titer of 5,000 units / g or more, and more preferably one with a proteolytic titer of 50,000 units / g or more. In this specification, the proteolytic titer is defined as the activity that increases the absorbance at a wavelength of 275 nm corresponding to 1 μg of L-tyrosine in the first minute of the reaction, using casein (milk-based) as a substrate, at 37°C and pH 6.0, with 1 unit being the activity. Protein degradation titer, sometimes called protein digestion capacity, can be measured by the method described in the examples below.

[0029] (B-a5) Glutathione Glutathione is a tripeptide (L-γ-glutamyl-L-cysteinyl-glycine) composed of glutamic acid, cysteine, and glycine, and has the effect of reducing disulfide bonds in proteins to sulfhydryl groups (SH groups).

[0030] The glutathione used in this invention may be an extract from plants, animals, or yeast, or it may be synthesized by known methods, but commercially available products can also be used. The glutathione may be reduced glutathione, oxidized glutathione, or a mixture thereof, but reduced glutathione is preferred because it is expected to exert anti-aging effects.

[0031] (B-a6) Lactic acid bacteria The lactic acid bacteria of this invention refer to bacteria that produce lactic acid through metabolism. The lactic acid bacteria that can be used in this invention may be live or dead, and in the case of dead bacteria, they may be lysates of the bacterial cells. Lactic acid bacteria powder can be obtained, for example, by removing unnecessary components such as the culture medium from cultured lactic acid bacteria or a lactic acid bacteria culture used for fermentation, and then pulverizing the bacterial cells of the lactic acid bacteria by a known method. The type of lactic acid bacteria is not particularly limited as long as it produces lactic acid as a metabolite, and examples include those that have been conventionally taken orally by animals such as humans, such as those of the genera Bifidobacterium, Lactobacillus, Enterococcus, Leuconostoc, Pediococcus, Staphylococcus, Tetragenococcus, and Bacillus. These may be used individually or in combination of two or more. Depending on the dosage form and quality of the composition of the present invention, those having properties such as heat resistance, acid resistance, sugar resistance, salt resistance, and spore-forming properties can be appropriately selected. There are no particular restrictions on how lactic acid bacteria are obtained; for example, lactic acid bacteria isolated from foods such as yogurt or vegetables, or commercially available products can be used.

[0032] The composition of the present invention may contain, as component (B), at least one plant material selected from the group consisting of grape, maca, pine bark, kudzu flower, Terminalia bellirica, Indian mangosteen, black ginger, and willowherb.

[0033] (B-b1) Grapes Grapes are plants belonging to the Vitaceae family. The grapes used in this invention can be the fruit, skin, seeds, leaves, etc., and are not particularly limited, but the fruit, seeds, or leaves are preferred. Furthermore, the grapes used can be any variety, such as European and American varieties (scientific name: Vitis vinifera) or American varieties (scientific name: Vitis labrusca), and are not particularly limited, but European and American varieties are preferred. In particular, red grapes of European and American varieties with red, purple, blue, dark blue, or nearly black skin and red flesh are preferred. The grapes used in this invention may be processed products of grapes, for example, dried grapes, dried and crushed grapes (crushed powder), extracts extracted with water, lower alcohol, or a mixture thereof (extract powder), or fermented products (fermented powder) can be used, and it is preferred to use extract powder, with extract powder extracted with ethanol being particularly preferred. As for the grapes used in the present invention, from the viewpoint of promoting GLP-1 secretion, suppressing blood glucose elevation, or improving dispersibility, extract powders of grape fruits, seeds, or leaves are preferred, and in particular, extract powder obtained by ethanol extraction of grape seeds is preferred.

[0034] (B-b2) Maca Maca is a perennial plant belonging to the genus Lepidium in the Brassicaceae family, native to Peru in South America, including species such as Lepidium meyenii. The root is preferred when used as maca.

[0035] (B-b3) Pine bark Pine is an evergreen coniferous tree belonging to the genus Pinus in the family Pinaceae. Examples of pine bark sources include French maritime pine (Pinus Martima), larch, Japanese black pine, Japanese red pine, Japanese white pine, Korean pine, Japanese stone pine, Ryukyu pine, Japanese white pine, longleaf pine, and Japanese white pine. Among these, French maritime pine is preferred due to its superior anti-aging properties.

[0036] Pine bark contains proanthocyanidins as one of its main components. Proanthocyanidins are a group of compounds consisting of condensed polymers with a degree of polymerization of 2 or more, with flavan-3-ol and / or flavan-3,4-diol as constituent units.

[0037] As for pine bark, processed products of collected pine bark can be used. Processing forms include dried products, fermented products, pulverized products, juices, and extracts. Solvents used for extraction include organic solvents such as water, methanol, ethanol, isopropanol, acetone, 1,3-butylene glycol, ethylene glycol, propylene glycol, glycerin, ethyl acetate, diethyl ether, and hexane, as well as acidic aqueous solutions such as acetic acid, citric acid, or aqueous solutions thereof, or mixed solvents thereof. The temperature of the extraction solvent can be appropriately set between room temperature and below the boiling point depending on the solvent used. Processing forms of the processed product include (dried) powder, pulverized products, granules, pastes, and liquids.

[0038] In the present invention, the pine bark used is preferably pulverized, water (warm water, hot water) extract, ethanol extract, or aqueous ethanol extract, with water (warm water, hot water) extract, ethanol extract, or aqueous ethanol extract being more preferable. Aqueous ethanol extract is the most preferred because it provides excellent sugar uptake. In addition, commercially available pine bark products can be used; for example, aqueous ethanol extract of pine bark (Flavanogenol®) manufactured by Toyo Shinyaku Co., Ltd. can be used.

[0039] Furthermore, the pine bark preferably contains a condensate polymer with a degree of polymerization of 2 or more as a proanthocyanidin. In particular, proanthocyanidins containing a large amount of a condensate polymer with a low degree of polymerization are preferred. Examples of low condensate polymers include a condensate polymer with a degree of polymerization of 2 to 30 (2 to 30-mers), a condensate polymer with a degree of polymerization of 2 to 10 (2 to 10-mers) is preferred, and a condensate polymer with a degree of polymerization of 2 to 4 (2 to 4-mers) is even more preferred. In this specification, polymers with a degree of polymerization of 2 to 4 are referred to as OPC (oligomeric proanthocyanidin). The pine bark in the composition of the present invention preferably contains 10% by mass or more of OPC, more preferably 20% by mass or more, and even more preferably 30% by mass or more.

[0040] (B-b4) Kudzu flower Kudzu is a climbing perennial plant belonging to the genus Pueraria in the family Fabaceae. In the composition of the present invention, kudzu flowers may be collected at any stage from bud to fully bloomed flower, or a mixture of flowers collected at each stage may be used. There are no particular restrictions on the type of kudzu, but examples include Pueraria thomsonii, Pueraria lobata, Pueraria thunbergiana, etc. Pueraria thomsonii is preferred from the viewpoint of anti-obesity, body fat reduction, and fat metabolism promotion effects.

[0041] In the composition of the present invention, kudzu flower can be a processed product of kudzu flowers. The processed product of kudzu flowers may be an extract or a pulverized product. When using a kudzu flower extract, examples of extraction solvents include ethanol (including aqueous ethanol), water, polar organic solvents other than ethanol (e.g., methanol, propanol, butanol, isopropanol, acetone, diethyl ether, etc.), and non-polar solvents (hexane, cyclohexane, propane, etc.), but ethanol, water, and aqueous ethanol are particularly preferred. The extract may be powdered by spray drying or concentration to dryness, or it may be a kudzu flower extract obtained by adding an excipient such as dextrin during spray drying or concentration to dryness and then granulating it. When using pulverized kudzu flowers, examples include dried pulverized powder obtained by drying and pulverizing kudzu flowers.

[0042] (B-b5) Terminalia bellirica Terminalia belliricca is a broad-leaved tree belonging to the genus Terminalia in the family Combretaceae. In this invention, any part may be used, but parts excluding the seeds are preferred, and from the viewpoint of anti-aging effects, parts of the fruit excluding the seeds (pericarp and pulp) are more preferably used.

[0043] The Terminalia bellirica of the present invention can be used in processed forms such as pulverized material, juice, or extract. Examples of pulverized material include powder and granules. Juice and extract may be in liquid form, but can also be used as a paste or dried powder. When used as a paste or dried powder, it may be manufactured using only the paste or processed together with excipients. Extracts can be obtained by extraction using a suitable solvent. Examples of usable solvents include water, methanol, ethanol, isopropanol, acetone, 1,3-butylene glycol, ethylene glycol, propylene glycol, glycerin, acetic acid, ethyl acetate, diethyl ether, hexane, or mixtures thereof. In the present invention, it is preferable to use water, methanol, ethanol, or mixtures thereof, in order to effectively exhibit the effects of suppressing blood glucose elevation, inhibiting sugar absorption, suppressing blood triglyceride elevation, and inhibiting fat absorption. The temperature during extraction can be appropriately adjusted from room temperature to a temperature below the boiling point of the extraction solvent. In the present invention, commercially available products can be used; for example, Terminalia bellirica extract manufactured by Toyo Shinyaku Co., Ltd. can be used.

[0044] (B-b6) Indian Mangosteen Indian mangosteen is a plant belonging to the genus Garcinia (also known as the family Hypericaceae), and its scientific name is Garcinia indica. It is also known as kokum, Indian mangosteen, small mangosteen, wild mangosteen, and red mangosteen.

[0045] The parts of the Indian mangosteen used are not particularly limited, and leaves, fruits, and other parts can be suitably combined and used. However, the fruit is preferred, and the pulp and peel are particularly preferred, as they allow the effects of the present invention to be more effectively exhibited.

[0046] In the present invention, Indian mangosteen may be used as is after harvesting, or processed Indian mangosteen (processed Indian mangosteen). When processed Indian mangosteen is used, for example, it can be used in the form of powder, granules, juice, or extract. The juice or extract may be in liquid or slurry form, but it is preferable to use dried powder. Among these, powder and extract are preferred, and extract is particularly preferred, as they allow the effects of the present invention to be exhibited more effectively. In the present invention, the term "extract" is a concept that includes dried extract powder (extract that has been dried and powdered). The processed Indian mangosteen may be manufactured by methods commonly known to those skilled in the art, or it may be one that is available on the market.

[0047] (B-b7) Black Ginger Black ginger, scientifically known as Kaempferia Parviflora, is not particularly limited to any plant of the genus Kaempferia in the family Zingiberaceae, known to grow wild in Southeast Asia and other regions. For example, parts such as the roots, stems, leaves, flowers, and branches can be used, but the roots and stems are preferred. Black ginger may be used in its unprocessed state as harvested, or as a processed product obtained by subjecting it to a predetermined treatment after harvesting. Examples of processed products include, but are not limited to, dried powder, pulverized material and its dried powder, juice and its dried powder, extract and its dried powder. Specifically, dried powder is preferred from the viewpoint of ease of processing, storage, and transportation, as well as versatility in usage. Commercially available products can be used in this invention.

[0048] (B-b8) Willowherb Willowherb (Chamerion angustifolium) is a perennial herb belonging to the genus Chamerion in the family Onagraceae. The parts of the willowherb that can be used are not particularly limited; the leaves, flowers, petals, seeds, stems, and / or above-ground parts can all be used.

[0049] In the present invention, the willowherb may be used as is after harvesting, or processed willowherb (processed willowherb product) may be used. When processed willowherb is used, examples include pulverized material, juice, and extract, but an extract is preferred in order to more effectively exhibit the effects of the present invention. The solvent used for extraction may be either a polar solvent or a nonpolar solvent, and water, methanol, ethanol, acetone, ethyl acetate, diethyl ether, n-hexane, etc., and mixtures thereof can be used, but water, aqueous ethanol, and ethanol are preferred in order to more effectively exhibit the effects of the present invention. The extraction method is not particularly limited as long as it is a method that is normally acceptable when extracting plant components, but examples include solid-liquid extraction methods such as heated extraction and supercritical fluid extraction. The juice and extract may be in liquid form, but can also be used as a paste or dried powder. When used as a paste or dried powder, it may be manufactured using only that material, or it may be processed together with excipients. Furthermore, the obtained processed product may be further subjected to chemical treatment, enzymatic treatment, or purification treatment. The processed willowherb product may be manufactured by methods commonly known to those skilled in the art, or it may be one that is available on the market.

[0050] The composition of the present invention may contain, as component (B), at least one vitamin selected from the group consisting of vitamin B and vitamin D.

[0051] (B-c1) Vitamin B Vitamin B is a water-soluble vitamin that functions as a coenzyme in energy metabolism. In this invention, vitamin B refers to eight types of vitamins: vitamin B1, vitamin B2, vitamin B6, vitamin B12, niacin, pantothenic acid, folic acid, and biotin. Any of the eight vitamin B types mentioned above may be used as the vitamin B used in this invention, but vitamin B1 is preferred from the viewpoint of particularly demonstrating the effects of this invention.

[0052] (B-c1) Vitamin D Examples of vitamin D and its derivatives include vitamin D1, vitamin D3 (active vitamin D), and ergosterol. In this invention, vitamin D3 is preferred from the viewpoint of particularly demonstrating the effects of the present invention.

[0053] The composition of the present invention may also contain leucine as component (B).

[0054] (B-d1) Leucine Leucine is a type of amino acid, a branched-chain amino acid, and one of the essential amino acids in humans, and is abbreviated as Leu or L. Leucine exists in isomers such as L-, D-, and DL-, and any of them can be used in the oral composition of the present invention, but the L-isomer is particularly preferred from the viewpoint of particularly demonstrating the effects of the present invention.

[0055] 2. Composition of the present invention

[0056] (Content of component A) There are no particular restrictions on the content of component (A) incorporated into the composition of the present invention, and its blending ratio can be appropriately set over a wide range depending on various conditions such as purpose, shape, and target of use. For example, when the composition of the present invention is an oral composition and a solid preparation (powder, granules, tablets, capsules, chewables, etc.), the content of component (A) in the composition of the present invention is preferably 0.001 to 80% by mass, more preferably 0.01 to 70% by mass, and particularly preferably 0.1 to 65% by mass, from the viewpoint of anti-aging effect. When the composition of the present invention is an oral composition and a liquid preparation (liquid, gel, paste, etc.), the content of component (A) in the composition of the present invention is preferably 0.0001 to 30% by mass, more preferably 0.001 to 20% by mass, and particularly preferably 0.01 to 10% by mass, from the viewpoint of anti-aging effect. When the composition of the present invention is an external composition, the content of component (A) in the composition of the present invention is preferably 0.000001 to 20% by mass, more preferably 0.00001 to 10% by mass, and particularly preferably 0.0001 to 5% by mass, from the viewpoint of anti-aging effect.

[0057] (Content of component B) There are no particular restrictions on the content of component (B) incorporated into the composition of the present invention, and its blending ratio can be appropriately set over a wide range depending on various conditions such as purpose, shape, and target of use. For example, when the composition of the present invention is an oral composition and a solid preparation (powder, granules, tablets, capsules, chewables, etc.), the content of component (B) in the composition of the present invention is preferably 0.001 to 50% by mass, more preferably 0.01 to 20% by mass, and particularly preferably 0.1 to 10% by mass, from the viewpoint of anti-aging effect. When the composition of the present invention is an oral composition and a liquid preparation (liquid, gel, paste, etc.), the content of component (B) in the composition of the present invention is preferably 0.0001 to 20% by mass, more preferably 0.001 to 10% by mass, and particularly preferably 0.01 to 5% by mass, from the viewpoint of anti-aging effect. When the composition of the present invention is an external composition, the content of component (B) in the composition of the present invention is preferably 0.000001 to 10% by mass, more preferably 0.00001 to 5% by mass, and particularly preferably 0.0001 to 1% by mass, from the viewpoint of anti-aging effect.

[0058] (Mass ratio of component B to component A) In the composition of the present invention, there are no particular restrictions on the mass ratio of component (A) to component (B), and the blending ratio can be appropriately set over a wide range depending on various conditions such as purpose, shape, and target of use. However, from the viewpoint of further enhancing the effects of the present invention, the lower limit of the parts by mass of component (B) to 1 part by mass of component (A) is preferably 0.0001 parts by mass or more, and particularly preferably 0.001 parts by mass or more. Furthermore, from the viewpoint of further enhancing the effects of the present invention, the upper limit of the parts by mass of component (B) to 1 part by mass of component (A) is more preferably 1 part by mass or less, and particularly preferably 0.5 parts by mass or less. for example

[0059] (Daily intake amount, etc.)

[0060] The daily intake of component (A) incorporated into the composition of the present invention is not particularly limited for adults, but from the viewpoint of enjoying the effects of the present invention to the fullest extent, it is preferably 0.01 mg to 1000 mg, and more preferably 0.1 mg to 500 mg.

[0061] The daily intake of component (B) incorporated into the composition of the present invention is not particularly limited for adults, but from the viewpoint of enjoying the effects of the present invention to the fullest extent, it is preferably 0.0001 mg to 50 mg, and more preferably 0.01 mg to 20 mg.

[0062] When the composition of the present invention is an oral composition, it may be taken before meals, between meals, after meals, or at the same time as a meal. However, from the viewpoint of anti-aging effects, it is preferable to take it before meals, after meals, or at the same time as a meal, and more preferably after meals.

[0063] When the composition of the present invention is an external composition, the amount used is not particularly limited and can be appropriately selected considering various factors such as the age, weight, constitution, and application site of the individual being treated.

[0064] When the composition of the present invention is a topical composition, there are no particular limitations on the frequency of application to the subject, but from the viewpoint of anti-aging effect, 1 to 5 times / day is preferred, and 1 to 3 times / day is more preferred.

[0065] (Use as an oral composition) The composition of the present invention may contain only nicotinamide mononucleotide and / or pyrroloquinoline quinone and components selected from genistein, isoquercitrin, ginsenoside, papain, glutathione, lactic acid bacteria, grapes, maca, pine bark, kudzu flower, Terminalia bellirica, Indian mangosteen, black ginger, willowherb, vitamin B, vitamin D, and leucine, or it may contain other components in addition to these. If the composition of the present invention is an oral composition, the other components may include, for example, protein, dietary fiber such as water-soluble dietary fiber and insoluble dietary fiber, vitamins other than those contained in components (A) and (B), minerals, plants other than those contained in component (B), algae, microorganisms other than lactic acid bacteria, etc. Furthermore, as needed, other commonly used ingredients in the food industry include dextrin, sugars such as starch, oligosaccharides, sweeteners, acidulants, colorants, thickeners, glazing agents, excipients, nutritional supplements, binders, lubricants, stabilizers, diluents, bulking agents, emulsifiers, food additives, and seasonings.

[0066] (Use as a topical composition) When the composition of the present invention is an external composition, the other components mentioned above include various pharmacoactive ingredients (reactive oxygen species scavengers, antioxidants, anti-inflammatory agents, cell activators, vitamins other than those contained in components (A) and (B), hormones, extracts from plants other than those contained in component (B) that have these effects, etc.), other oils (unsaturated fatty acids such as linoleic acid, linolenic acid, palmitic acid, DHA, EPA and their derivatives, oils extracted from plants and animals such as linseed oil, coconut oil, jojoba oil, olive oil, squalane, squalene, horse oil, rice bran oil, castor oil and their derivatives, etc.), and purifiers. Examples of humectants include collagen or its breakdown products, soy peptides, amino acids, mucopolysaccharides such as hyaluronic acid, amino sugars such as chondroitin, sugars such as trehalose, and seaweed; thickeners such as alginic acid or its salts, cellulose derivatives, acrylic acid polymers or their derivatives, glucomannan, and pectin; gelling agents; surfactants such as lecithin, betaine, fatty acid esters, amino acid derivatives; anionic surfactants, cationic surfactants, nonionic surfactants, and amphoteric surfactants; UV absorbers; UV scattering agents such as zinc oxide and titanium dioxide; and pigments.

[0067] The composition of the present invention can be used as an oral composition or as a topical composition applied to the skin or scalp, and is preferably used as an oral composition from the viewpoint of its anti-aging effect.

[0068] The form of the composition of the present invention is not particularly limited and can be any form. When the composition of the present invention is an oral composition, examples of forms include powder, granules, tablets, liquid, gel, paste, capsules such as hard capsules and soft capsules, caplets, tablets, gels, jellies, gummies, wafers, biscuits, cookies, cakes, chewables, syrups, and sticks. From the viewpoint of anti-aging effects, the composition of the present invention is preferably in the form of granules, tablets, capsules, or liquid, and more preferably in the form of granules, tablets, or capsules. Here, "granules" refers to a composition obtained by granulating powder, which may be taken directly or dissolved in a liquid such as water before taking. "Gel" refers to a composition containing water and a thickener or gelling agent, and having viscosity or elasticity.

[0069] When the composition of the present invention is an external composition, its form may include, for example, a lotion, emulsion, gel, cream, ointment, powder, granules, etc. Specifically, examples include lotions, cosmetic creams, emulsions, creams, packs, hair tonics, hair creams, shampoos, hair rinses, treatments, body washes, facial cleansers, soaps, foundations, face powders, lipsticks, lip glosses, blushes, eyeshadows, hair styling products, hair growth products, aqueous ointments, oily ointments, eye drops, eye washes, patches, gels, and the like.

[0070] The packaging form of the composition of the present invention is not particularly limited and can be appropriately selected depending on the dosage form, etc., but examples include blister packs such as PTP, strip packaging, heat seals, aluminum pouches, film packaging using plastic or synthetic resin, glass containers such as vials, and plastic containers such as ampoules.

[0071] (Use as an anti-aging composition) The composition of the present invention can be used as an anti-aging composition. When the present invention is an anti-aging composition, it is not particularly limited as long as it can be distinguished from other products in that it is used for anti-aging. For example, any product that displays that it has an anti-aging function on the product itself, packaging, instructions, or promotional materials is included in the scope of the present invention. Examples include so-called health foods such as pharmaceuticals (including quasi-drugs), functional foods whose efficacy has been approved by a designated institution, such as Foods for Specified Health Uses, Foods with Nutrient Function Claims, and Foods with Function Claims, as well as cosmetics. Examples of so-called health foods include those that display phrases such as "firm days," "lively days," "want to stay youthful," "don't let age get the better of you," "want to continue to shine beautifully," and "aging care." The anti-aging composition of the present invention may display component (A) or component (B) as an active ingredient, but is not limited to products where component (A) or component (B) is displayed as an active ingredient on the product packaging, etc. For example, the active ingredient may not be specified, or components other than component (A) and component (B) may be displayed as active ingredients.

[0072] (Use as a composition for maintaining and improving vitality, etc.) The composition of the present invention can increase the production of adenosine triphosphate (ATP) by activating mitochondria. As a result, it exhibits excellent effects such as maintaining and improving vitality, maintaining the health of the skin or mucous membranes, and promoting protein metabolism.

[0073] Here, ATP, which is energy, is necessary for cells to function. Approximately 90% of this ATP is produced by oxidative phosphorylation in mitochondria in almost all cells except red blood cells. Therefore, it is thought that promoting mitochondrial activity, which is a common energy production mechanism regardless of cell type, can lead to the maintenance and improvement of various cell functions. Specifically, these effects include maintaining and improving vitality, maintaining the health of the skin or mucous membranes, and promoting protein metabolism.

[0074] For example, neuronal cell death, a contributing factor to decreased vitality, is known to be induced by decreased mitochondrial activity (Kitagawa, Kazuo, et al. "Results and Clinical Applications of Neuronal Cell Death Research." Stroke 30.6(2008):862-868). Therefore, promoting mitochondrial activity is thought to help maintain and improve vitality.

[0075] Furthermore, it is known that in epidermal cells, promoting mitochondrial activity enhances the production of fibroblast growth factor (FGF) and epidermal growth factor (EGF) (Kazuhiko Honjo. "Cytological effects of plant fermented paste AO via mitochondria and antioxidant activity." Pharmacology and Therapeutics 45.7(2017):1141-1152.). Also, in airway epithelial cells, decreased mitochondrial activity is known to cause excessive mucin secretion (Aguilera-Aguirre, Leopoldo, et al. "Mitochondrial dysfunction increases allergic airway inflammation." The Journal of Immunology 183.8(2009):5379-5387.). Therefore, it is thought that promoting mitochondrial activity contributes to maintaining the health of the skin or mucous membranes.

[0076] Furthermore, it has been reported that promoting mitochondrial activity in muscle cells increases muscle mass (Sugimoto, Ken. "3. Mitochondrial function of skeletal muscle and the significance of Myokine in sarcopenia." Journal of the Japan Geriatrics Society 49.2(2012):199-202.). Therefore, it is thought that promoting mitochondrial activity contributes to promoting protein metabolism.

[0077] Therefore, the compositions of the present invention can be used as compositions for maintaining and improving vitality, compositions for maintaining the health of the skin or mucous membranes, and compositions for promoting protein metabolism.

[0078] If the present invention is a composition for maintaining and improving vitality, it is not particularly limited as long as it can be distinguished from other products in that it is used for maintaining and improving vitality. For example, any product that displays that it has the function of maintaining and improving vitality on the product itself, packaging, instructions, or promotional materials is included in the scope of the present invention. Examples include so-called health foods such as pharmaceuticals (including quasi-drugs), functional foods whose efficacy has been approved by a designated institution, such as Foods for Specified Health Uses, Foods with Nutrient Function Claims, and Foods with Function Claims. Examples of Foods with Nutrient Function Claims include those that display "maintain vitality," "keep vitality," "support daily vitality," "suppress decline in vitality," "for those concerned about vitality," "enhance vitality," "promote vitality," "vitality," etc. The present invention's composition for maintaining and improving vitality may display component (A) or component (B) as the active ingredient, but is not limited to products where component (A) or component (B) is displayed as the active ingredient on the product packaging, etc. For example, the active ingredient may not be specified, or the active ingredient may be an ingredient other than (A) and (B).

[0079] If the present invention is a composition for maintaining the health of the skin or mucous membranes, it is not particularly limited as long as it can be distinguished from other products in that it is used for maintaining the health of the skin or mucous membranes. For example, any product in which the body, packaging, instructions, or promotional materials of the present invention indicate that it has the function of maintaining the health of the skin or mucous membranes is included in the scope of the present invention. Examples include so-called health foods such as pharmaceuticals (including quasi-drugs), functional foods whose efficacy has been approved by a designated institution, such as Foods for Specified Health Uses, Foods with Nutrient Function Claims, and Foods with Function Claims. Examples of Foods with Nutrient Function Claims include those which indicate "helps maintain the health of the skin and mucous membranes," "maintains skin health," "supports the maintenance of the health of the skin and mucous membranes," "keeps skin healthy," "improves skin condition," "maintains moisture of mucous membranes," and "maintains the barrier function of the skin and mucous membranes." The present invention's composition for maintaining the health of the skin or mucous membranes may indicate the above-mentioned component (A) or component (B) as the active ingredient, but is not limited to products in which component (A) or component (B) is indicated as the active ingredient on the product packaging, etc. For example, the active ingredient may not be specified, or the active ingredient may be an ingredient other than (A) and (B).

[0080] If the present invention is a composition for promoting protein metabolism, it is not particularly limited as long as it can be distinguished from other products in that it is used to promote protein metabolism. For example, any product that displays that it has the function of promoting protein metabolism on the product itself, packaging, instructions, or promotional materials is included in the scope of the present invention. Examples include so-called health foods such as pharmaceuticals (including quasi-drugs), functional foods whose efficacy has been approved by a designated institution, such as Foods for Specified Health Uses, Foods with Nutrient Function Claims, and Foods with Function Claims. Examples of Foods with Nutrient Function Claims include those that display "supports protein absorption," "promotes muscle formation," "supports muscle strength maintenance," "keeps muscles healthy," "supports protein supplementation after exercise," "helps maintain muscle mass," and "participates in protein metabolism and contributes to maintaining health." The present invention's composition for promoting protein metabolism may display the above-mentioned component (A) or component (B) as the active ingredient, but is not limited to products where component (A) or component (B) is displayed as the active ingredient on the product packaging, etc. For example, the active ingredient may not be specified, or the active ingredient may be an ingredient other than (A) and (B). [Examples]

[0081] The present invention will be described in more detail below with reference to examples, but the present invention is not limited to these examples, and can take various forms as long as it can solve the problems of the present invention.

[0082] (Test: Evaluation of anti-aging effects) This study evaluated the amount of activated mitochondria. Mitochondria are organelles that play a central role in energy production within cells, and it is known that decreased mitochondrial activity and function are closely related to diseases such as cancer, aging, Alzheimer's disease, and Parkinson's disease, as well as skin aging. When mitochondrial function declines due to aging, the amount of reactive oxygen species generated when mitochondria produce energy increases, making mitochondrial DNA more susceptible to damage and leading to further functional decline. Conversely, when mitochondrial function is good, the amount of reactive oxygen species generated decreases, and it is thought that more energy can be produced. Therefore, by confirming the mitochondrial activation effect, it becomes possible to evaluate the anti-aging effect.

[0083] (Test substance) The following substances were used as test substances. • Nicotinamide mononucleotide: β-NMN produced by fermentation using commercially available yeast was used. • Pyrroloquinoline quinone: PQQ produced using a commercially available fermentation method was used. • Genistein: A commercially available genistein reagent was used. • Isoquercitrin: A commercially available isoquercitrin reagent was used. • Ginsenoside: A commercially available ginsenoside Rg1 reagent was used. • Papain: A commercially available papain reagent was used. • Glutathione: A commercially available reduced glutathione reagent was used. • Lactic acid bacteria: Using Bacillus coagulans • Grapes: We used an extract powder obtained by ethanol extraction of commercially available grape seeds. • Maca: Commercially available dried maca root powder was used. • Pine bark: Aqueous ethanol extract of pine bark (Flavanogenol®) manufactured by Toyo Shinyaku Co., Ltd. was used. • Kudzu flowers: Commercially available dried and pulverized kudzu flower powder was used. • Terminalia bellirica: Terminalia bellirica extract (manufactured by Toyo Shinyaku Co., Ltd.) was used. • Indian mangosteen: Commercially available product was used. • Black ginger: A commercially available powdered rhizome extract containing aqueous ethanol was used. • Willowherb: A commercially available aqueous ethanol extract of willowherb was used. • Vitamin B: A commercially available vitamin B1 reagent was used. • Vitamin D: A commercially available vitamin D3 reagent was used. • Leucine: A commercially available L-leucine reagent was used. • Resveratrol: Resveratrol was used as a comparative example, as it is known to have anti-aging effects. Commercially available resveratrol was used.

[0084] (Preparation of the test substance) Each test substance was prepared using DMEM medium containing 0.5% DMSO and 10% fetal bovine serum (FBS). The mixing ratios of the test substances used in the following tests are shown in Tables 1-4.

[0085] (Mitochondrial activity measurement) (1) Normal human dermal fibroblasts (NHDF) were cultured in a 75 cm² flask in a 37°C, 5 vol. % CO₂ incubator using DMEM medium containing 10% fetal bovine serum (FBS). (2) Cells suspended by trypsin treatment were seeded at a cell density of 8 × 10^3 cells / well in each well of a 96-well plate (collagen coated) and pre-cultured for 24 hours in a 37°C, 5V %CO2 incubator. (3) After removing the culture medium from each well, 100 μL / well of culture medium containing the test substance, prepared to the specified concentration, was added and incubated for 24 hours at 37°C in a 5 vol. %CO2 incubator. (4) DMEM medium containing 0.5% DMSO and 10% FBS was used as the culture medium, and the total concentration of the test substance in the medium was set to 1 μg / mL. (5) After 24 hours of incubation, the culture medium was removed, and each well was washed twice with 200 μL of serum-free DMEM. Then, 50 μL of 1 μM rhodamine diluted with serum-free DMEM was added to each well. (6) After staining the cells by incubating them in a 37°C, 5V %CO2 incubator for 60 minutes, the reagents were removed and the cells were washed twice with PBS 200 μL / well. (7) 200 μL of PBS was added, and the fluorescence intensity (excitation wavelength Ex. 507 nm, fluorescence wavelength Em. 529 nm) was measured. Based on the obtained data, mitochondrial activity (% of control) was calculated. (8)% of control =(Data sample - Data blank) / (Data control - Data blank)× 100 (9) Tables 1-4 show the relative values ​​when the control value without the test substance is set to 100.

[0086] The denominator (baseline), "Data control - Data blank," is the value obtained by subtracting the fluorescence intensity of "blank" from the fluorescence intensity of the sample without the test substance (Control). On the other hand, the numerator, "Data sample - Data blank," is the value obtained by subtracting the fluorescence intensity of "blank" from the fluorescence intensity of the sample with the test substance added. Since the value obtained by subtracting the fluorescence intensity of blank from the fluorescence intensity of the sample is proportional to the amount of activated mitochondria, the calculated "% of control" serves as an indicator of mitochondrial activity.

[0087] [Table 1]

[0088] [Table 2]

[0089] [Table 3]

[0090] [Table 4]

[0091] In the groups administered with component (A) and at least one of component (B) (Examples 1-49), higher mitochondrial activity was observed compared to the groups administered with only one of component (A) or (B) (Comparative Example 1-19). In the group administered with only one of component (B) (Comparative Example 3-19), no increase in mitochondrial activity was observed compared to the control group. Therefore, it was found that combining component (A) and at least one selected from component (B) exerts a mitochondrial activity-promoting effect. From this, it was found that the composition of the present invention exhibits excellent anti-aging effects by containing component (A) and at least one selected from component (B). On the other hand, while the groups administered resveratrol, which is known to have anti-aging effects, and component (A) (Comparative Examples 20-21) showed an increase in mitochondrial activity compared to the control group, the increase in mitochondrial activity was not observed compared to the group administered NMN alone (Comparative Example 1) or the group administered PQQ alone (Comparative Example 2). This indicates that combining NMN or PQQ with resveratrol does not result in superior anti-aging effects.

[0092] (Example: Granules) After mixing the raw materials according to the formulations in Table 5-8, fluid bed granulation was performed using a granulator to produce the granules described in Example 51-101. All of the granules described in Example 51-101 exhibited anti-aging effects when 3 g per day was dissolved in 100 ml of a solvent such as water and taken orally. All of the granules in Example 51-101 can be taken orally continuously and safely over a long period of time.

[0093] [Table 5]

[0094] [Table 6]

[0095] [Table 7]

[0096] [Table 8]

[0097] (Example: Tablets) After mixing the raw materials according to the formulations in Table 9-12, tablets were produced using a rotary tablet press to manufacture the tablets described in Manufacturing Examples 53-104. The tablets were manufactured with a diameter of 8 mmφ, a thickness of 4.5 mm, a weight of 250 mg, and a hardness of 5 kgf or more. The tablets described in Examples 102-153 only required 1 to 2 tablets per day, and when taken with 100 ml of water, they exhibited anti-aging effects. All of the tablets in Examples 102-153 can be safely and continuously taken orally over a long period of time.

[0098] [Table 9]

[0099] [Table 10]

[0100] [Table 11]

[0101] [Table 12] [Industrial applicability]

[0102] The composition of the present invention exhibits excellent anti-aging effects, and therefore has high industrial utility.

Claims

[Claim 1] (A) Nicotinamide mononucleotide and / or pyrroloquinoline quinone, (B) At least one specific other material selected from the group consisting of (a) to (d) below, A composition characterized by containing the following: (a) At least one functional material selected from the group consisting of genistein, isoquercitrin, ginsenoside, papain, glutathione, and lactic acid bacteria. (b) At least one plant material selected from the group consisting of grapes, maca, pine bark, kudzu flowers, Terminalia bellirica, Indian mangosteen, black ginger, and willowherb. (c) At least one vitamin selected from the group consisting of vitamins B and D (d) Leucine

Images